
|Articles|February 1, 2003
Ruboxistaurin results: Eli Lilly plans more trials
Indianapolis-Eli Lilly and Co. will delay the submission of its ruboxistaurin for the treatment of diabetic retinopathy and diabetic macular edema (DME) after two clinical trials failed to achieve satisfactory results on disease progression.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
2
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
3
Development of maculopathy associated with systemic medications
4
Periorbital rejuvenation: Past, present, and next
5

















































.png)


